Experimental drug combo targets Hard-to-Treat cancers

NCT ID NCT03218826

Completed Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new drug called AZD8186 combined with the chemotherapy docetaxel in 23 patients with advanced solid tumors that have PTEN or PIK3CB gene mutations. The main goal was to find the safest dose and understand side effects. The study is complete, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD8186 and docetaxel
What this could lead to: If this works, it could point toward a new treatment option for advanced solid tumors with PTEN or PIK3CB mutations.
What could go wrong: This is a very early, small phase 1 trial focused on safety and dosing, not effectiveness. The combination may cause significant side effects and may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm cancer castration-resistant prostate carcinoma metastatic malignant neoplasm metastatic neoplasm metastatic prostate carcinoma neoplasm Neoplasm Metastasis prostate cancer prostate carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CARCINOMA ADVANCED MALIGNANT SOLID NEOPLASM ADVANCED PROSTATE CARCINOMA ANATOMIC STAGE III BREAST CANCER AJCC V8 ANATOMIC STAGE IIIA BREAST CANCER AJCC V8 ANATOMIC STAGE IIIB BREAST CANCER AJCC V8 ANATOMIC STAGE IIIC BREAST CANCER AJCC V8 ANATOMIC STAGE IV BREAST CANCER AJCC V8 CASTRATION-RESISTANT PROSTATE CARCINOMA METASTATIC BREAST CARCINOMA METASTATIC MALIGNANT SOLID NEOPLASM METASTATIC PROSTATE CARCINOMA PROGNOSTIC STAGE III BREAST CANCER AJCC V8 PROGNOSTIC STAGE IIIA BREAST CANCER AJCC V8 PROGNOSTIC STAGE IIIB BREAST CANCER AJCC V8 PROGNOSTIC STAGE IIIC BREAST CANCER AJCC V8 PROGNOSTIC STAGE IV BREAST CANCER AJCC V8 STAGE III PROSTATE CANCER AJCC V8 STAGE IIIA PROSTATE CANCER AJCC V8 STAGE IIIB PROSTATE CANCER AJCC V8 STAGE IIIC PROSTATE CANCER AJCC V8 STAGE IV PROSTATE CANCER AJCC V8 STAGE IVA PROSTATE CANCER AJCC V8 STAGE IVB PROSTATE CANCER AJCC V8 TRIPLE-NEGATIVE BREAST CARCINOMA UNRESECTABLE SOLID NEOPLASM

Contacts and locations

Locations

Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287, United States
M D Anderson Cancer Center

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States
National Cancer Institute Developmental Therapeutics Clinic

Bethesda, Maryland, 20892, United States
National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States
UCHealth University of Colorado Hospital

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.